Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

According to data presented during the 2021 American Society of Clinical Oncology Annual Meeting, the triplet combination of polatuzumab vedotin, rituximab, and lenalidomide demonstrated a tolerable safety profile and showed promising activity in patients with relapsed/refractory DLBCL. Among the entire patient population, median PFS was 6.3 months (95% CI, 4.5-9.7) and median OS was 10.9 months (95% CI, 10.9-not evaluated). For patients with a complete response, neither the 9-month median PFS nor median OS had been reached.